Identifying knowledge gaps in the labeling of medications for geriatric patients.
作者信息
Hinshaw Trevor, Kapusnik-Uner Joan, Zarowitz Barbara, Matuszewski Karl
出版信息
P T. 2013 Sep;38(9):535-40.
Abstract
The authors found that two-thirds of drugs approved by the FDA in recent years lacked adequate efficacy and safety information for use in older patients. With an expected doubling of the elderly population by 2040, it is time for pharmaceutical manufacturers to incorporate more robust prescribing information into their product labels of drugs used in this patient population.
摘要
相似文献
1
Identifying knowledge gaps in the labeling of medications for geriatric patients.
P T. 2013 Sep;38(9):535-40.
2
Specific Prescribing Information for Geriatric Use in the 2019 Product Labeling for Novel New Drug Approvals.
Sr Care Pharm. 2021 Sep 1;36(9):455-465. doi: 10.4140/TCP.n.2021.455.
3
Potential risks of pharmacy compounding.
Drugs R D. 2013 Mar;13(1):1-8. doi: 10.1007/s40268-013-0005-9.
4
Assessment of geriatric information on the drug label for commonly prescribed drugs in older people.
J Am Geriatr Soc. 2005 May;53(5):891-4. doi: 10.1111/j.1532-5415.2005.53273.x.
5
Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
Ther Innov Regul Sci. 2018 Nov;52(6):771-777. doi: 10.1177/2168479018759662. Epub 2018 Mar 5.
6
International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
Clin Pharmacol Ther. 2020 Mar;107(3):530-540. doi: 10.1002/cpt.1640. Epub 2019 Nov 10.
7
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
J Diabetes Complications. 2017 Dec;31(12):1719-1727. doi: 10.1016/j.jdiacomp.2017.08.005. Epub 2017 Aug 12.
8
Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.
Front Pharmacol. 2022 Oct 17;13:1031992. doi: 10.3389/fphar.2022.1031992. eCollection 2022.
9
Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU.
Soc Sci Med. 2021 Jul;280:114049. doi: 10.1016/j.socscimed.2021.114049. Epub 2021 May 20.
10
Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing.
PLoS One. 2011;6(8):e23336. doi: 10.1371/journal.pone.0023336. Epub 2011 Aug 17.
引用本文的文献
1
Older adult participation in cancer clinical trials: A systematic review of barriers and interventions.
CA Cancer J Clin. 2021 Jan;71(1):78-92. doi: 10.3322/caac.21638. Epub 2020 Oct 1.
2
Phase 1 Clinical Trials in the Elderly: Enrollment Challenges.
J Adv Pract Oncol. 2020 Jul;11(5):494-501. doi: 10.6004/jadpro.2020.11.5.5. Epub 2020 Jul 1.
3
Improving Quality and Value of Cancer Care for Older Adults.
Am Soc Clin Oncol Educ Book. 2017;37:383-393. doi: 10.1200/EDBK_175442.
本文引用的文献
1
Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy.
N Engl J Med. 2012 Nov 22;367(21):1972-4. doi: 10.1056/NEJMp1209034.
2
Off-label prescribing in older patients.
Drugs Aging. 2012 Jun 1;29(6):427-34. doi: 10.2165/11633520-000000000-00000.
3
Pediatric information in drug product labeling.
JAMA. 2012 May 9;307(18):1914-5. doi: 10.1001/jama.2012.3435.
4
Therapeutic experimentation in the elderly.
Geriatr Nurs. 2012 Mar-Apr;33(2):127-30. doi: 10.1016/j.gerinurse.2012.02.002.
5
American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.
J Am Geriatr Soc. 2012 Apr;60(4):616-31. doi: 10.1111/j.1532-5415.2012.03923.x. Epub 2012 Feb 29.
6
Emergency hospitalizations for adverse drug events in older Americans.
N Engl J Med. 2011 Nov 24;365(21):2002-12. doi: 10.1056/NEJMsa1103053.
7
Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.
Br J Clin Pharmacol. 2004 Jan;57(1):6-14. doi: 10.1046/j.1365-2125.2003.02007.x.
Zotero 插件